person · Reporting owner

Sigal Charles Elliott

Disclosed activity across 4 companies

Tapewire entity: 43528
SEC CIK: 0001661908

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132	Director	May 20, 2026	May 22, 2026
Adaptimmune Therapeutics PLCADAP · Entity 9824	Director	July 03, 2023	July 03, 2023
Vir Biotechnology, Inc.VIR · Entity 4522	Director	May 27, 2026	May 28, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALNYLAM PHARMACEUTICALS, INC.

Report date May 20, 2026 · Filed May 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,446	Reported balance After 2026-05-20 transaction · row 1 1 source row Row 1 · 2026-05-20 · Grant · Acquired 671 · Balance 1,446 F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $298.48 · Expires 2036-05-20	Direct	1,441	Reported balance After 2026-05-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-20 · Grant · Acquired 1,441 · Balance 1,441 F3: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
Common StockSEC Table I · non-derivative	Indirectby Trust	2,000	Reported balance Holding disclosure · report date 2026-05-20 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 2,000 F2: Shares held by Sigal Family Investments, LLC, of which the reporting person is Managing Member.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

F2: Shares held by Sigal Family Investments, LLC, of which the reporting person is Managing Member.

F3: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Adaptimmune Therapeutics PLC

Report date July 03, 2023 · Filed July 03, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option to purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.16 · Expires 2033-07-03	Direct	933,317	Reported balance After 2023-07-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-07-03 · Grant · Acquired 933,317 · Balance 933,317 F1: The exercise price was converted from GBP0.12 based on an exchange rate of $U.S. 1.270841 to GBP1.00. The actual exercise price will be the pounds sterling amount.

Filing footnotes · ownership attribution and instrument terms

F1: The exercise price was converted from GBP0.12 based on an exchange rate of $U.S. 1.270841 to GBP1.00. The actual exercise price will be the pounds sterling amount.

Vir Biotechnology, Inc.

Report date May 27, 2026 · Filed May 28, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	39,806	Reported balance After 2026-05-27 transaction · row 1 1 source row Row 1 · 2026-05-27 · Grant · Acquired 8,000 · Balance 39,806 F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F2: The RSUs will vest in full on May 27, 2027.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.10 · Expires 2036-05-26	Direct	16,000	Reported balance After 2026-05-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-27 · Grant · Acquired 16,000 · Balance 16,000 F4: The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.
Common StockSEC Table I · non-derivative	IndirectBy Sigal Family Investments, LLC	10,000	Reported balance Holding disclosure · report date 2026-05-27 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 10,000 F3: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.

F2: The RSUs will vest in full on May 27, 2027.

F3: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F4: The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Surface Oncology, Inc.

Report date September 08, 2023 · Filed September 08, 2023

Section 16 reporting ended · disclosed 2023-09-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2023-09-08 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2023-09-08 · Disposition to issuer · Disposed 45,453 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated as of June 15, 2023 (the "Merger Agreement"), by and among the Issuer, Coherus BioSciences, Inc. ("Coherus"), Crimson Merger Sub I, Inc., a direct, wholly owned subsidiary of Coherus ("Merger Sub I"), and Crimson Merger Sub II, LLC, a direct, wholly owned subsidiary of Coherus ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of September 8, 2023 (the "Effective Time"), with Surface surviving such merger as a direct, wholly owned subsidiary of Coherus (the "First Merger"), and, as part of the same overall transaction, promptly after the First Merger, the surviving corporation of the First Merger merged with and into Merger Sub II, with Merger Sub II surviving such merger. F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer was cancelled and converted into the right to receive (i) 0.1960 (the "Exchange Ratio") shares of common stock of Coherus and (ii) one contingent value right (each, a "CVR") representing a contractual right to receive contingent future conditional payments pursuant to the terms of a Contingent Value Rights Agreement by and between Coherus and Computershare Inc. F3: The shares are held by Sigal Family Investments, LLC. The Reporting Person may be deemed to have voting and dispositive power with respect to the shares held by Sigal Family Investments, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.35	Direct	0	Reported balance After 2023-09-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-09-08 · Disposition to issuer · Disposed 113,636 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated as of June 15, 2023 (the "Merger Agreement"), by and among the Issuer, Coherus BioSciences, Inc. ("Coherus"), Crimson Merger Sub I, Inc., a direct, wholly owned subsidiary of Coherus ("Merger Sub I"), and Crimson Merger Sub II, LLC, a direct, wholly owned subsidiary of Coherus ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of September 8, 2023 (the "Effective Time"), with Surface surviving such merger as a direct, wholly owned subsidiary of Coherus (the "First Merger"), and, as part of the same overall transaction, promptly after the First Merger, the surviving corporation of the First Merger merged with and into Merger Sub II, with Merger Sub II surviving such merger. F4: At the Effective Time, each option to purchase shares of the Issuer's Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $1.0354 (any such option, an "In-the-Money Option") was cancelled and converted into the right to receive (i) 0.1960 shares of common stock of Coherus and (ii) a number of CVRs equal to the number of shares of Surface common stock underlying such In-the-Money Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated as of June 15, 2023 (the "Merger Agreement"), by and among the Issuer, Coherus BioSciences, Inc. ("Coherus"), Crimson Merger Sub I, Inc., a direct, wholly owned subsidiary of Coherus ("Merger Sub I"), and Crimson Merger Sub II, LLC, a direct, wholly owned subsidiary of Coherus ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of September 8, 2023 (the "Effective Time"), with Surface surviving such merger as a direct, wholly owned subsidiary of Coherus (the "First Merger"), and, as part of the same overall transaction, promptly after the First Merger, the surviving corporation of the First Merger merged with and into Merger Sub II, with Merger Sub II surviving such merger.

F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer was cancelled and converted into the right to receive (i) 0.1960 (the "Exchange Ratio") shares of common stock of Coherus and (ii) one contingent value right (each, a "CVR") representing a contractual right to receive contingent future conditional payments pursuant to the terms of a Contingent Value Rights Agreement by and between Coherus and Computershare Inc.

F3: The shares are held by Sigal Family Investments, LLC. The Reporting Person may be deemed to have voting and dispositive power with respect to the shares held by Sigal Family Investments, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

F4: At the Effective Time, each option to purchase shares of the Issuer's Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $1.0354 (any such option, an "In-the-Money Option") was cancelled and converted into the right to receive (i) 0.1960 shares of common stock of Coherus and (ii) a number of CVRs equal to the number of shares of Surface common stock underlying such In-the-Money Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 27, 2026 Filed May 28, 2026 23:25 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantStock Option (Right to Buy) · Derivative	16,000	$0.00 Strike: $9.10	$0.00	Disclosure SEC source: 0001628280-26-038966 · wk-form4_1780010743.xml · derivative · entry 3 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2036-05-26 F4 · shares: The shares subject to the stock option will vest and become exercisable in full on May 27, 2027. Read SEC document
May 27, 2026 Filed May 28, 2026 23:25 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantCommon Stock	8,000	$0.00	$0.00	Disclosure SEC source: 0001628280-26-038966 · wk-form4_1780010743.xml · nonDerivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,806 F1 · kind: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F2 · shares: The RSUs will vest in full on May 27, 2027. Read SEC document
May 20, 2026 Filed May 22, 2026 20:20 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (Right to Buy) · Derivative	1,441	$0.00 Strike: $298.48	$0.00	Disclosure SEC source: 0001178670-26-000042 · form4.xml · derivative · entry 3 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,441 Underlying: Common Stock · 1,441 shares Expires 2036-05-20 F3 · derivative.exercise_date: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document
May 20, 2026 Filed May 22, 2026 20:20 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantCommon Stock	671	$0.00	$0.00	Disclosure SEC source: 0001178670-26-000042 · form4.xml · nonDerivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,446 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document
May 30, 2025 Filed Jun 2, 2025 23:31 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantStock Option (Right to Buy) · Derivative	16,000	$0.00 Strike: $4.94	$0.00	Disclosure SEC source: 0001628280-25-028902 · wk-form4_1748907056.xml · derivative · entry 3 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2035-05-29 F4 · shares: The shares subject to the stock option will vest and become exercisable in full on May 30, 2026. Read SEC document
May 30, 2025 Filed Jun 2, 2025 23:31 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantCommon Stock	8,000	$0.00	$0.00	Disclosure SEC source: 0001628280-25-028902 · wk-form4_1748907056.xml · nonDerivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,806 F1 · kind: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F2 · shares: The RSUs will vest in full on May 30, 2026. Read SEC document
May 08, 2025 Filed May 12, 2025 20:04 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	1,558	$0.00 Strike: $258.35	$0.00	Disclosure SEC source: 0001735276-25-000060 · edgardoc.xml · derivative · entry 3 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,558 Underlying: Common Stock · 1,558 shares Expires 2035-05-08 F3 · derivative.exercise_date: The stock option vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document
May 08, 2025 Filed May 12, 2025 20:04 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantCommon Stock	775	$0.00	$0.00	Disclosure SEC source: 0001735276-25-000060 · edgardoc.xml · nonDerivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 775 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document
May 30, 2024 Filed Jun 3, 2024 16:18 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantStock Option (Right to Buy) · Derivative	16,000	$0.00 Strike: $10.39	$0.00	Disclosure SEC source: 0001628280-24-026221 · wk-form4_1717431521.xml · derivative · entry 3 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2034-05-29 Read SEC document
May 30, 2024 Filed Jun 3, 2024 16:18 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantCommon Stock	8,000	$0.00	$0.00	Disclosure SEC source: 0001628280-24-026221 · wk-form4_1717431521.xml · nonDerivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,806 Read SEC document
May 16, 2024 Filed May 20, 2024 20:08 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	5,228	$0.00 Strike: $151.22	$0.00	Disclosure SEC source: 0001735276-24-000052 · edgardoc.xml · derivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,228 Underlying: Common Stock · 5,228 shares Expires 2034-05-16 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document
September 08, 2023 Filed Sep 8, 2023 16:00 UTC	Surface Oncology, Inc. SURF · Entity 109857	Disposition to issuerStock Option (Right to Buy) · Derivative	113,636	$0.00 Strike: $0.35	$0.00	Disclosure SEC source: 0001209191-23-048762 · doc4.xml · derivative · entry 2 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 113,636 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated as of June 15, 2023 (the "Merger Agreement"), by and among the Issuer, Coherus BioSciences, Inc. ("Coherus"), Crimson Merger Sub I, Inc., a direct, wholly owned subsidiary of Coherus ("Merger Sub I"), and Crimson Merger Sub II, LLC, a direct, wholly owned subsidiary of Coherus ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of September 8, 2023 (the "Effective Time"), with Surface surviving such merger as a direct, wholly owned subsidiary of Coherus (the "First Merger"), and, as part of the same overall transaction, promptly after the First Merger, the surviving corporation of the First Merger merged with and into Merger Sub II, with Merger Sub II surviving such merger. F4 · derivative.exercise_date: At the Effective Time, each option to purchase shares of the Issuer's Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $1.0354 (any such option, an "In-the-Money Option") was cancelled and converted into the right to receive (i) 0.1960 shares of common stock of Coherus and (ii) a number of CVRs equal to the number of shares of Surface common stock underlying such In-the-Money Option. F4 · derivative.expiration_date: At the Effective Time, each option to purchase shares of the Issuer's Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $1.0354 (any such option, an "In-the-Money Option") was cancelled and converted into the right to receive (i) 0.1960 shares of common stock of Coherus and (ii) a number of CVRs equal to the number of shares of Surface common stock underlying such In-the-Money Option. Read SEC document
September 08, 2023 Filed Sep 8, 2023 16:00 UTC	Surface Oncology, Inc. SURF · Entity 109857	Disposition to issuerCommon Stock	45,453	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-048762 · doc4.xml · nonDerivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated as of June 15, 2023 (the "Merger Agreement"), by and among the Issuer, Coherus BioSciences, Inc. ("Coherus"), Crimson Merger Sub I, Inc., a direct, wholly owned subsidiary of Coherus ("Merger Sub I"), and Crimson Merger Sub II, LLC, a direct, wholly owned subsidiary of Coherus ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of September 8, 2023 (the "Effective Time"), with Surface surviving such merger as a direct, wholly owned subsidiary of Coherus (the "First Merger"), and, as part of the same overall transaction, promptly after the First Merger, the surviving corporation of the First Merger merged with and into Merger Sub II, with Merger Sub II surviving such merger. F2 · price: At the Effective Time, each issued and outstanding share of common stock of the Issuer was cancelled and converted into the right to receive (i) 0.1960 (the "Exchange Ratio") shares of common stock of Coherus and (ii) one contingent value right (each, a "CVR") representing a contractual right to receive contingent future conditional payments pursuant to the terms of a Contingent Value Rights Agreement by and between Coherus and Computershare Inc. F3 · ownership.nature: The shares are held by Sigal Family Investments, LLC. The Reporting Person may be deemed to have voting and dispositive power with respect to the shares held by Sigal Family Investments, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document
July 03, 2023 Filed Jul 3, 2023 21:02 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	933,317	$0.00 Strike: $0.16	$0.00	Disclosure SEC source: 0001104659-23-077668 · tm2320409-4_4seq1.xml · derivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 933,317 Underlying: Ordinary Shares · 933,317 shares Expires 2033-07-03 F1 · derivative.exercise_price: The exercise price was converted from GBP0.12 based on an exchange rate of $U.S. 1.270841 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document
May 22, 2023 Filed May 24, 2023 18:33 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantStock Option (Right to Buy) · Derivative	12,054	$0.00 Strike: $25.74	$0.00	Disclosure SEC source: 0001209191-23-031840 · doc4.xml · derivative · entry 3 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,054 Underlying: Common Stock · 12,054 shares Expires 2033-05-21 Read SEC document
May 22, 2023 Filed May 24, 2023 18:33 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantCommon Stock	6,027	$0.00	$0.00	Disclosure SEC source: 0001209191-23-031840 · doc4.xml · nonDerivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,806 Read SEC document
May 18, 2023 Filed May 19, 2023 20:06 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	3,454	$0.00 Strike: $189.87	$0.00	Disclosure SEC source: 0001735276-23-000067 · edgardoc.xml · derivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,454 Underlying: Common Stock · 3,454 shares Expires 2033-05-18 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document
March 01, 2023 Filed Mar 2, 2023 21:27 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	PurchaseCommon Stock	2,500	$22.73	$56,815.50	Disclosure SEC source: 0001209191-23-014673 · doc4.xml · nonDerivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Sigal Family Investments, LLC Disclosed balance after: 10,000 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sigal Family Investments, LLC on October 21, 2022, of which the reporting person is the manager. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.595 to $22.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
January 05, 2023 Filed Jan 9, 2023 16:51 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	PurchaseCommon Stock	2,500	$24.96	$62,395.50	Disclosure SEC source: 0001209191-23-002507 · doc4.xml · nonDerivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Sigal Family Investments, LLC Disclosed balance after: 7,500 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sigal Family Investments, LLC on October 21, 2022, of which the reporting person is the manager. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.81 to $25.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
January 04, 2023 Filed Jan 5, 2023 22:00 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	PurchaseCommon Stock	2,500	$25.25	$63,136.25	Disclosure SEC source: 0001209191-23-001932 · doc4.xml · nonDerivative · entry 2 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Sigal Family Investments, LLC Disclosed balance after: 5,000 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sigal Family Investments, LLC on October 21, 2022, of which the reporting person is the manager. F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.08 to $25.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
January 03, 2023 Filed Jan 5, 2023 22:00 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	PurchaseCommon Stock	2,500	$25.60	$63,992.50	Disclosure SEC source: 0001209191-23-001932 · doc4.xml · nonDerivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Sigal Family Investments, LLC Disclosed balance after: 2,500 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sigal Family Investments, LLC on October 21, 2022, of which the reporting person is the manager. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.41 to $25.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document
August 22, 2022 Filed Aug 24, 2022 20:08 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	4,456	$0.00 Strike: $217.91	$0.00	Disclosure SEC source: 0001735276-22-000074 · edgardoc.xml · derivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,456 Underlying: Common Stock · 4,456 shares Expires 2032-08-22 F1 · derivative.exercise_date: The stock option will vest as to one third of the shares on each of the first, second and third anniversaries of the date of grant. Read SEC document
July 01, 2022 Filed Jul 1, 2022 21:01 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	737,050	$0.00 Strike: $0.28	$0.00	Disclosure SEC source: 0001104659-22-076896 · tm2220260-3_4seq1.xml · derivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 737,050 Underlying: Ordinary Shares · 737,050 shares Expires 2032-07-02 F1 · derivative.exercise_price: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document
June 08, 2022 Filed Jun 10, 2022 20:00 UTC	Surface Oncology, Inc. SURF · Entity 109857	GrantStock Option (Right to Buy) · Derivative	24,000	$0.00 Strike: $2.01	$0.00	Disclosure SEC source: 0001209191-22-036151 · doc4.xml · derivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: The Options shall vest in twelve equal monthly installments following the date of grant or, if earlier, upon the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. Read SEC document
May 23, 2022 Filed May 25, 2022 22:09 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantStock Option (Right to Buy) · Derivative	12,810	$0.00 Strike: $24.14	$0.00	Disclosure SEC source: 0001209191-22-031959 · doc4.xml · derivative · entry 2 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,810 Underlying: Common Stock · 12,810 shares Expires 2032-05-22 Read SEC document
May 23, 2022 Filed May 25, 2022 22:09 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantCommon Stock	6,405	$0.00	$0.00	Disclosure SEC source: 0001209191-22-031959 · doc4.xml · nonDerivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,779 Read SEC document
July 01, 2021 Filed Jul 2, 2021 21:01 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	474,385	$0.00 Strike: $0.71	$0.00	Disclosure SEC source: 0001104659-21-088967 · tm2121284-3_4seq1.xml · derivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,385 Underlying: Ordinary Shares · 474,385 shares Expires 2031-07-02 F1 · derivative.exercise_price: The exercise price was converted from GBP0.51 based on an exchange rate of $U.S. 1.3807 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document
June 08, 2021 Filed Jun 10, 2021 16:30 UTC	Surface Oncology, Inc. SURF · Entity 109857	GrantStock Option (Right to Buy) · Derivative	17,700	$0.00 Strike: $7.69	$0.00	Disclosure SEC source: 0001209191-21-039464 · doc4.xml · derivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,700 Underlying: Common Stock · 17,700 shares Expires 2031-06-08 F1 · derivative.exercise_date: The Options shall vest in full upon the earlier to occur of the first anniversary of the date of grant or the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. Read SEC document
May 21, 2021 Filed May 25, 2021 20:48 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantStock Option (Right to Buy) · Derivative	6,748	$0.00 Strike: $45.28	$0.00	Disclosure SEC source: 0001209191-21-035717 · doc4.xml · derivative · entry 2 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,748 Underlying: Common Stock · 6,748 shares Expires 2031-05-20 Read SEC document
May 21, 2021 Filed May 25, 2021 20:48 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantCommon Stock	3,374	$0.00	$0.00	Disclosure SEC source: 0001209191-21-035717 · doc4.xml · nonDerivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,374 Read SEC document
July 10, 2020 Filed Jul 15, 2020 00:22 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantStock Option (Right to Buy) · Derivative	57,777	$0.00 Strike: $48.71	$0.00	Disclosure SEC source: 0001209191-20-042454 · doc4.xml · derivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,777 Underlying: Common Stock · 57,777 shares Expires 2030-07-10 F1 · derivative.exercise_date: 1/3 of the shares subject to the stock option vest and become exercisable on July 10, 2021, and the remaining shares vest in 24 equal monthly installments thereafter. Read SEC document
July 10, 2020 Filed Oct 13, 2020 23:16 UTC Amendment	Vir Biotechnology, Inc. VIR · Entity 4522	GrantStock Option (Right to Buy) · Derivative	28,394	$0.00 Strike: $48.71	$0.00	Disclosure SEC source: 0001209191-20-054743 · doc4a.xml · derivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,394 Underlying: Common Stock · 28,394 shares Expires 2030-07-09 F1 · derivative.exercise_date: 1/3 of the shares subject to the stock option vest and become exercisable on July 10, 2021, and the remaining shares vest in 24 equal monthly installments thereafter. Read SEC document
July 01, 2020 Filed Jul 1, 2020 21:07 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	184,258	$0.00 Strike: $1.67	$0.00	Disclosure SEC source: 0001104659-20-079786 · a4.xml · derivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,258 Underlying: Ordinary Shares · 184,258 shares Expires 2030-07-02 F1 · derivative.exercise_price: The exercise price was converted from GBP1.35 based on an exchange rate of $U.S. 1.2387 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document
June 10, 2020 Filed Jun 12, 2020 08:00 UTC	Surface Oncology, Inc. SURF · Entity 109857	GrantStock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $4.35	$0.00	Disclosure SEC source: 0001209191-20-036181 · doc4.xml · derivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: This option shall vest in full upon the earlier to occur of the first anniversary of the date of grant or the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director. Read SEC document
October 01, 2019 Filed Oct 3, 2019 16:33 UTC	Surface Oncology, Inc. SURF · Entity 109857	GrantStock Option (Right to Buy) · Derivative	13,572	$0.00 Strike: $1.17	$0.00	Disclosure SEC source: 0001209191-19-052219 · doc4.xml · derivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,572 Underlying: Common Stock · 13,572 shares Expires 2029-10-01 F1 · derivative.exercise_date: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer and committee fees of $9,750 which would have been paid quarterly. This option shall vest in full on December 31, 2019. Read SEC document
July 02, 2019 Filed Jul 3, 2019 21:00 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	234,407	$0.00 Strike: $0.61	$0.00	Disclosure SEC source: 0001104659-19-039326 · a4.xml · derivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,407 Underlying: Ordinary Shares · 234,407 shares Expires 2029-07-02 F1 · derivative.exercise_price: The exercise price was converted from GBP0.48 based on an exchange rate of $U.S. 1.2638 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document
July 01, 2019 Filed Jul 2, 2019 17:19 UTC	Surface Oncology, Inc. SURF · Entity 109857	GrantStock Option (Right to Buy) · Derivative	5,696	$0.00 Strike: $2.79	$0.00	Disclosure SEC source: 0001209191-19-040466 · doc4.xml · derivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,696 Underlying: Common Stock · 5,696 shares Expires 2029-07-01 F1 · derivative.exercise_date: This option was issued to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer and committee fees of $9,750 which would have been paid quarterly. This option shall vest in full on September 30, 2019. Read SEC document
June 05, 2019 Filed Jun 6, 2019 16:46 UTC	Surface Oncology, Inc. SURF · Entity 109857	GrantStock Option (Right to Buy) · Derivative	12,100	$0.00 Strike: $3.69	$0.00	Disclosure SEC source: 0001209191-19-035103 · doc4.xml · derivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,100 Underlying: Common Stock · 12,100 shares Expires 2029-06-05 F1 · derivative.exercise_date: This option shall vest in full upon the earlier to occur of the first anniversary of the date of grant or the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director. Read SEC document
July 02, 2018 Filed Jul 5, 2018 16:06 UTC	Surface Oncology, Inc. SURF · Entity 109857	GrantStock Option (Right to Buy) · Derivative	8,882	$0.00 Strike: $16.83	$0.00	Disclosure SEC source: 0000899243-18-019432 · doc4.xml · derivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,882 Underlying: Common Stock · 8,882 shares Expires 2028-07-02 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 24 equal monthly installments after May 1, 2018. Read SEC document
June 22, 2018 Filed Jun 26, 2018 21:00 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	154,809	$0.00 Strike: $2.18	$0.00	Disclosure SEC source: 0001104659-18-042320 · a4.xml · derivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,809 Underlying: Ordinary Shares · 154,809 shares Expires 2028-06-22 F1 · derivative.exercise_price: The exercise price was converted from GBP1.65 based on an exchange rate of $U.S. 1.3250 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document
April 23, 2018 Filed Apr 23, 2018 16:15 UTC	Surface Oncology, Inc. SURF · Entity 109857	ConversionSeries A Preferred Stock · Derivative	100,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-025822 · doc4.xml · derivative · entry 2 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 45,453 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public offering without payment or further consideration and had no expiration date. F1 · price: The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public offering without payment or further consideration and had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public offering without payment or further consideration and had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public offering without payment or further consideration and had no expiration date. F1 · derivative.underlying_shares: The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public offering without payment or further consideration and had no expiration date. F2 · ownership.nature: The shares are held by Sigal Family Investments, LLC. The Reporting Person may be deemed to have voting and dispositive power with respect to the shares held by Sigal Family Investments, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document
April 23, 2018 Filed Apr 23, 2018 16:15 UTC	Surface Oncology, Inc. SURF · Entity 109857	ConversionCommon Stock	45,453	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-025822 · doc4.xml · nonDerivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 45,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public offering without payment or further consideration and had no expiration date. F2 · ownership.nature: The shares are held by Sigal Family Investments, LLC. The Reporting Person may be deemed to have voting and dispositive power with respect to the shares held by Sigal Family Investments, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document
July 03, 2017 Filed Jul 3, 2017 21:01 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	220,788	$0.00 Strike: $0.75	$0.00	Disclosure SEC source: 0001104659-17-043263 · a4.xml · derivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,788 Underlying: Ordinary Shares · 220,788 shares Expires 2027-07-03 F1 · derivative.exercise_price: The exercise price was converted from GBP0.58 based on the closing midpoint exchange rate for the U.S. dollar on the day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.